Inhibikase welcomes new board member
Malone, the chief regulatory officer at Sanofi, replaces Dr. Steven Gilman, who retired from the board after over four years of service.
"As Inhibikase completes the transition to the clinic with its novel treatments for infectious disease, such as IkT-001Pro for Progressive Multifocal Leukoencephalopathy (PML), Dr. Malone's regulatory expertise will become invaluable to Inhibikase as it advances its discussion with U.S. and European regulators on the approval path for our novel products," Dr. Milton Werner, Inhibikase Therapeutics president and CEO, said. "Hilary brings unprecedented regulatory expertise into the company at a critical time in its development."
Malone brings to the table more than 20 years of experience. She has worked with drug development, as well as global regulatory affairs.
"I have been impressed by the progress that Inhibikase has made in bringing its pipeline of drug candidates to the clinic," Malone said. "I believe that the company's lead product has great potential to address the development of PML, and I look forward to working with the Inhibikase board and management to advance the portfolio and growth of the company."